Mga Batayang Estadistika
| CIK | 1878313 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MAIA Biotechnology, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissio |
|
| August 13, 2025 |
Exhibit 99.1 MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO – August 13, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted im |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41455 MAIA BIOTECHNOLOGY, INC. |
|
| July 28, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| July 28, 2025 |
Exhibit 99.1 MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment market Latest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of 17.8 months CHICAGO – July 28, 2025 – MAIA Biotechnology, Inc. (NYSE |
|
| July 17, 2025 |
Exhibit 99.1 MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy Manuscript featured in leading open-access peer-reviewed scientific journal Nucleic Acids Research CHICAGO – July 17, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company foc |
|
| July 17, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| July 9, 2025 |
Exhibit 99.1 MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer CHICAGO – July 09, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced dosing of the first patient in Taiwan in the expansion phase |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| June 26, 2025 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (“Agreement”) is made and entered into as of June 24, 2025 (“Effective Date”), between MAIA Biotechnology, Inc. (the “Company”) and Prevail Partners, LLC (“Prevail Partners”), Tax ID# 27-0256095. The Company and Prevail Partners are collectively referred to herein as the “Parties.” WITNESSETH WHEREAS, the Company identifies and de |
|
| June 24, 2025 |
Exhibit 99.1 MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway CHICAGO – June 24, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cance |
|
| June 24, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| June 18, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| June 18, 2025 |
Exhibit 99.3 MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies ● Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments CHICAGO – June 18, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing |
|
| June 17, 2025 |
Exhibit 10.1 MAIA BIOTECHNOLOGY, Inc. June 17, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: MAIA Biotechnology, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) a reduction in the Exercise Price (as defined in the respective Existing Warrants and as set forth on Exhibi |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| June 5, 2025 |
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial Exhibit 99.2 MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial CHICAGO – June 5, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of t |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| June 5, 2025 |
Exhibit 99.1 MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data CHICAGO – June 5, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targ |
|
| June 2, 2025 |
Exhibit 99.1 |
|
| June 2, 2025 |
Exhibit 99.2 |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31. 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| May 28, 2025 |
CORRECTING and REPLACING: MAIA Biotechnology Announces $695,000 Private Placement Exhibit 99.1 CORRECTING and REPLACING: MAIA Biotechnology Announces $695,000 Private Placement This is a correction of the announcement. The number of shares and expected proceeds from the private placement have been corrected to 463,332 shares and approximately $695,000. All other aspects of the announcement remain the same. The updated press release reads: MAIA BIOTECHNOLOGY ANNOUNCES PRIVATE PL |
|
| May 28, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 27, 2025, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 28, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 28, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 23, 2025 |
Exhibit 3.1 |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| May 22, 2025 |
Exhibit 3.1 |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q b UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41455 MAIA BIOTECHNOLOGY, INC. |
|
| May 6, 2025 |
MAIA Biotechnology Announces $1.08 Million Private Placement Exhibit 99.1 MAIA Biotechnology Announces $1.08 Million Private Placement CHICAGO, IL – May 5, 2025 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 719,999 shares of common s |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 6, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 5, 2025, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| May 6, 2025 |
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement Exhibit 99.2 CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement This is a correction of the announcement. The initial exercise date and term of the warrants purchased in the private placement have been corrected to one year following issuance and have a term of six years from the initial issuance date. All other aspects of the announcement remain the same. CHICAGO, IL – May 5 |
|
| May 6, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22. 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| April 22, 2025 |
Exhibit 99.1 |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use o |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, f |
|
| April 1, 2025 |
Exhibit 99.1 |
|
| April 1, 2025 |
Exhibit 99.2 MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders ● Lead compound THIO (ateganosine) is the only clinical-stage telomere-targeting anticancer agent throughout the field of cancer discovery ● Potential FDA filings in 2026 for accelerated approval from THIO-101 and early full approval from THIO-104 ● Full Shareho |
|
| April 1, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MAIA Biotechnology, Inc. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
Exhibit 99.1 |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, fo |
|
| March 26, 2025 |
Up to $11,200,000 Common Stock MAIA Biotechnology, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-273984 PROSPECTUS SUPPLEMENT (To Prospectus dated August 23, 2023) Up to $11,200,000 Common Stock MAIA Biotechnology, Inc. This prospectus supplement amends and supplements the information in the prospectus, dated August 23, 2023, filed as a part of our registration statement on Form S-3 (File No. 333-273984), as supplemented by our prospectus |
|
| March 26, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2025 |
Exhibit 99.1 |
|
| March 21, 2025 |
Description of Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the securities of MAIA Biotechnology, Inc. that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), certain provisions of Delaware law, our amended and restated certificate of incorporation |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41455 MAIA BIOTECHNOL |
|
| March 21, 2025 |
Exhibit 19.1 MAIA BIOTECHNOLOGY, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Company Securities Adopted: November 5, 2021 (updated February 8, 2024) In order to take an active role in the prevention of insider trading violations by its directors, officers and other employees, as well as by other related individuals, MAIA Biotechnology, Inc. (the “Company”) ha |
|
| March 19, 2025 |
Exhibit 99.1 MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO ● Nonproprietary drug name approval marks essential step in FDA approval process CHICAGO – March 19, 2025 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer |
|
| March 19, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| February 27, 2025 |
Exhibit 99.1 MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients CHICAGO – February 27, 2025 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today annou |
|
| February 27, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| February 25, 2025 |
MAIA Biotechnology Announces Non-Brokered Private Placement of approximately $1.43 million Exhibit 99.1 MAIA Biotechnology Announces Non-Brokered Private Placement of approximately $1.43 million CHICAGO – February 24, 2025 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggrega |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| February 25, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 25, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 24, 2025, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| February 25, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 19, 2025 |
MAIA Biotechnology Announces Private Placement of $2,715,000 Exhibit 99.1 MAIA Biotechnology Announces Private Placement of $2,715,000 CHICAGO – February 18, 2025 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,810,000 shares of comm |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| February 19, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 19, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 18, 2025, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| February 19, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 6, 2025 |
Employment Agreement, dated as of February 1, 2025, between the Company and Sergei Gryaznov. Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), dated as of February 01, 2025 (the “Effective Date”), between MAIA Biotechnology, Inc. (the “Company”) and Sergei Gryaznov (“Executive,” together with the Company, the “Parties” and, each, a “Party”). WHEREAS, the Company desires to continue to employ Executive, and Executive desires to accept such emplo |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 6, 2025 |
Employment Agreement, dated as of February 1, 2025, between the Company and Vlad Vitoc. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), dated as of February 01, 2025 (the “Effective Date”), between MAIA Biotechnology, Inc. (the “Company”) and Vlad Vitoc (“Executive,” together with the Company, the “Parties” and, each, a “Party”). WHEREAS, the Company desires to continue to employ Executive, and Executive desires to accept such employment |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4. 2025 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 5, 2025 |
Exhibit 99.1 MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ● Median overall survival (OS) from THIO treatment extends to 16.9 months ● Newest data strengthens regulatory strategy CHICAGO – February 04, 2025 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company |
|
| February 5, 2025 |
Exhibit 99.2 |
|
| January 27, 2025 |
Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212. |
|
| December 23, 2024 |
Up to $30,000,000 Common Stock MAIA Biotechnology, Inc. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-273984 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 23, 2023) Up to $30,000,000 Common Stock MAIA Biotechnology, Inc. This prospectus supplement amends and supplements the information in the prospectus, dated August 23, 2023, filed as a part of our registration statement on Form S-3 (File No. 333-273984), as supplemented |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| December 20, 2024 |
Exhibit 99.1 MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas CHICAGO – December 16, 2024 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the treatment of |
|
| December 20, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| December 10, 2024 |
MAIA Biotechnology Announces Private Placement of approximately $950,000 Exhibit 99.1 MAIA Biotechnology Announces Private Placement of approximately $950,000 CHICAGO – December 9, 2024 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 507,364 share |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| December 10, 2024 |
EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| December 10, 2024 |
Form of Securities Purchase Agreement EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 9, 2024, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| December 10, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q b UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41455 MAIA BIOTECHNOLOGY, INC. |
|
| November 8, 2024 |
Exhibit 99.1 |
|
| November 8, 2024 |
Exhibit 99.3 |
|
| November 8, 2024 |
Exhibit 99.2 |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| November 5, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| November 5, 2024 |
Exhibit 99.1 MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting ● Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) ● Poster to highlight long-term therapeutic benefits of THIO sequenced with cemi |
|
| October 29, 2024 |
EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| October 29, 2024 |
Form of Securities Purchase Agreement EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 28, 2024, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| October 29, 2024 |
MAIA Biotechnology Announces $2.44 Million Private Placement EX-99.1 Exhibit 99.1 MAIA Biotechnology Announces $2.44 Million Private Placement CHICAGO – October 28, 2024—MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,079,784 shares of |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| October 29, 2024 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| October 25, 2024 |
MAIA / MAIA Biotechnology, Inc. / Smith Stan - SC 13D/A Activist Investment SC 13D/A 1 d902674dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) MAIA BIOTECHNOLOGY, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 552641 102 (CUSIP Number) STAN V. SMITH 1165 North Clark Street, Suite 600 Chicago, IL 60610 Telephone: (312) 9 |
|
| October 25, 2024 |
MAIA / MAIA Biotechnology, Inc. / Louie Ngar Yee - SC 13D Activist Investment SC 13D 1 d903454dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.) MAIA BIOTECHNOLOGY, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 552641 102 (CUSIP Number) Louie Ngar Yee 444 West Lake Street, Suite 1700 Chicago, IL 60606 Telephone: (312) 416-8592 |
|
| October 25, 2024 |
MAIA / MAIA Biotechnology, Inc. / Vitoc Vlad - SC 13D Activist Investment SC 13D 1 d901744dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.) MAIA BIOTECHNOLOGY, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 552641 102 (CUSIP Number) Vlad Vitoc 444 West Lake Street, Suite 1700 Chicago, IL 60606 Telephone: (312) 416-8592 With |
|
| September 10, 2024 |
Exhibit 99.3 MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer ● 16 patients surpassed 12-month survival follow-up ● THIO’s substantial survival benefit in third line surpasses comparable standard-of-care overall survival of 5.8 months ● Median survival follow-up in third line was 10.6 months ● Treatment with THIO followed by Libtayo® has |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commis |
|
| September 10, 2024 |
Exhibit 99.2 |
|
| September 10, 2024 |
Exhibit 99.1 |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q b UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41455 MAIA BIOTECHNOLOGY, INC. |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| July 23, 2024 |
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent EX-99.1 2 ex99-1.htm Exhibit 99.1 MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent ● THIO followed by cemiplimab shown to be well tolerated throughout trial, with far lower toxicity compared to standard of care treatments ● 6 patients on trial regimen for more than 12 months have completed up to 21 cycles, with treatment ongoing CHICAGO – July 23, 2024 - |
|
| June 6, 2024 |
Exhibit 99.1 MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent ● New science for cancer therapy drives powerful value proposition ● Exceptional measures of efficacy by lead drug THIO in Phase 2 clinical trial ● Funding of more than $12M year-to-date, including $7.4 million in Q2’24 so far ● Secured continued insider investment |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| June 4, 2024 |
EX-99.2 Exhibit 99.2 Vlad Vitoc, MD, MBA Chief Executive Officer 444 West Lake Street, Suite 1700 - Chicago, IL 60606 (312) 416-8592 [email protected] (215) 971-5488 maiabiotech.com Telomere Targeting Immunotherapies for Cancer MAIA is an immuno-oncology company focused on the development and commercialization of first-in-class drugs intended to meaningfully improve and extend the lives of pe |
|
| June 4, 2024 |
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in EX-99.3 Exhibit 99.3 MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer THIO’s favorable disease control and overall response rates exceed reported standard-of-care data in third line treatment CHICAGO, IL – June 04, 2024 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company devel |
|
| June 4, 2024 |
EX-99.1 Exhibit 99.1 TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA June 2024 FORWARD-LOOKING STATEMENTS NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are forward-looking statements. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; statemen |
|
| June 3, 2024 |
EX-99.1 A Phase 2, Multi-Center, Open-Label, Dose-Optimization Study Evaluating Telomere-Targeting Agent THIO Sequenced with Cemiplimab in Patients with Advanced NSCLC: Updated Results Abstract 8601 T. Jankowski,1 T. Csoszi,2 L. Urban,3 T. Nagy,4 N. Chilingirova,5 M. Cholakova,6 R. Joshi,7 M. Moore,8 R. Ramlau,9 S. Soter,10 M. Kotlarski,11 K.D. Koynov,12 A. Mruk,13 B. Seidl,14 V. Minchev,15 V. Mul |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| June 3, 2024 |
EX-99.2 THIO-101 Supporting DECK ASCO 2024 Exhibit 99.2 Introduction Despite recent approvals for the first-line treatment of advanced Non-Small Cell Lung Cancer (NSCLC), long-term prognosis remains poor with a 5-year survival rate of 28%1 and limited options exist in patients refractory or resistant to immune checkpoint inhibitors (ICI). THIO (6-thio-2'-deoxyguanosine, also known as 6-thio-dG) is |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2024 |
Up to $11,280,000 Common Stock MAIA Biotechnology, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-273984 PROSPECTUS SUPPLEMENT (To Prospectus dated August 23, 2023) Up to $11,280,000 Common Stock MAIA Biotechnology, Inc. This prospectus supplement amends and supplements the information in the prospectus, dated August 23, 2023, filed as a part of our registration statement on Form S-3 (File No. 333-273984), as supplemented by our prospectus |
|
| May 14, 2024 |
Exhibit 4.1 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of May , 2024, by and between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and such holder identified on the signature page hereto (the “Holder”). WHEREAS, the Holder is the holder of that certain Common Stock Purchase Warrant |
|
| May 14, 2024 |
Exhibit 4.3 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of May , 2024, by and between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and such holder identified on the signature page hereto (the “Holder”). WHEREAS, the Holder is the holder of that certain Common Stock Purchase Warrant |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q b UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41455 MAIA BIOTECHNOLOGY, INC. |
|
| May 14, 2024 |
Exhibit 4.2 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of May , 2024, by and between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and such holder identified on the signature page hereto (the “Holder”). WHEREAS, the Holder is the holder of that certain Common Stock Purchase Warrant |
|
| May 7, 2024 |
Exhibit 99.1 |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 23, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 22, 2024, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| April 23, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 23, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 23, 2024 |
MAIA Biotechnology Announces $1.00 Million Private Placement EX-99.1 Exhibit 99.1 MAIA Biotechnology Announces $1.00 Million Private Placement CHICAGO, IL – April 23, 2024—MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| April 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MAIA Biotechnology, Inc. |
|
| April 19, 2024 |
As filed with the Securities and Exchange Commission on April 19, 2024 As filed with the Securities and Exchange Commission on April 19, 2024 Registration No. |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, f |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 26, 2024 |
MAIA Biotechnology Announces $1.33 Million Private Placement Exhibit 99.1 MAIA Biotechnology Announces $1.33 Million Private Placement CHICAGO, IL – March 26, 2024 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 578,643 shares of commo |
|
| March 26, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 25, 2024, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 25, 2024 |
Up to $4,950,000 Common Stock MAIA Biotechnology, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-273984 PROSPECTUS SUPPLEMENT (To Prospectus dated August 23, 2023) Up to $4,950,000 Common Stock MAIA Biotechnology, Inc. This prospectus supplement amends and supplements the information in the prospectus, dated August 23, 2023, filed as a part of our registration statement on Form S-3 (File No. 333-273984), as supplemented by our prospectus s |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2024 |
Exhibit 97.1 MAIA BIOTECHNOLOGY, INC. CLAWBACK POLICY 1. Introduction The Board of Directors (the “Board”) of MAIA Biotechnology, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this Clawback Policy (this “Policy”), which provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from |
|
| March 21, 2024 |
Exhibit 21.1 Subsidiaries MAIA Biotechnology Australia Pty Ltd., an Australian corporation MAIA Biotechnology Romania S.R.L. a Romanian subsidiary. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41455 MAIA BIOTECHNOL |
|
| March 21, 2024 |
Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the securities of MAIA Biotechnology, Inc. that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), certain provisions of Delaware law, our amended and restated certificate of incorporation |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2024 |
Form of Investor Warrant (included as part of Exhibit 10.1) EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 11, 2024, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and c |
|
| March 8, 2024 |
Exhibit 99.2 MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting ● THIO and ionizing radiation combination shown to significantly decrease cell proliferation and produce potent anticancer effects in highly aggressive, treatment-resistant childhood brain cancer CHICAGO, IL – |
|
| March 8, 2024 |
Exhibit 99.1 MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients ● Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, third-line non-small cell lung cancer (NSCLC) ● ORR of 38% significantly exceeds standard of care ORR in NSCLC third-line in patients without a targetable mutation who |
|
| March 8, 2024 |
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference Exhibit 99.3 MAIA Biotechnology to Participate in the 36th Annual ROTH Conference CHICAGO, IL – March 07, 2024 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 in Dana Point, California |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| March 6, 2024 |
Exhibit 99.1 March 2024 Dear fellow shareholders, At MAIA Biotechnology, our tenacious pursuit of innovative medicines to improve and extend people’s lives with cancer has led us to the forefront of cancer research. As we wrap up the Phase 2 clinical trial of our lead molecule THIO in non-small cell lung cancer (NSCLC) and pursue additional indications and a pipeline of next-generation THIO-like m |
|
| March 6, 2024 |
Exhibit 99.2 MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders ● THIO-101 Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications and next-generation molecules continues ● Shareholder Letter available in Investor Relations section of MAIA’s corporate website. C |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| February 27, 2024 |
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor Exhibit 99.1 MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor ● New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL – February 27, 2024 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company de |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| February 23, 2024 |
MAIA Biotechnology Completes Enrollment in Exhibit 99.1 MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer • Topline data expected in second half of 2024 • THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL – February 22, 2024 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Co |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2024 |
Up to $1,445,000 Common Stock MAIA Biotechnology, Inc. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-273984 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 23, 2023) Up to $1,445,000 Common Stock MAIA Biotechnology, Inc. We have entered into an At The Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”), relating to the sale of our common stock, par value $ |
|
| February 14, 2024 |
At The Market Offering Agreement between MAIA Biotechnology, Inc. and H.C. Wainwright & Co., LLC Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT February 14, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: MAIA Biotechnology, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this |
|
| January 30, 2024 |
EX-99.1 Exhibit 99.1 MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds • New patent would extend coverage and expand potential value of MAIA’s telomere-targeting platform globally CHICAGO, IL – January 24, 2024 -MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| January 18, 2024 |
EX-99.1 Exhibit 99.1 MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024 • Lead candidate THIO maintains unprecedented disease control rates in Phase 2 non-small cell lung cancer (NSCLC) clinical trial • Multiple clinical milestones ahead for THIO-101 Phase 2 trial • Company enters 2024 with robust clinical pipeline in m |
|
| December 21, 2023 |
MAIA Biotechnology Announces Dose Selection in EX-99.1 Exhibit 99.1 MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer • Selected dose shows unprecedented disease control and overall response rates in a NSCLC clinical trial CHICAGO, IL – December 19, 2023 – MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing t |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| November 17, 2023 |
EX-10.2 Exhibit 10.2 LOCK-UP AGREEMENT November 15, 2023 Re: Securities Purchase Agreement, dated as of November 15, 2023 (the “Purchase Agreement”), between MAIA Biotechnology, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement” |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| November 17, 2023 |
EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| November 17, 2023 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| November 17, 2023 |
MAIA Biotechnology, Inc. 2,424,243 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-273984 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 23, 2023) MAIA Biotechnology, Inc. 2,424,243 Shares of Common Stock We are offering 2,424,243 shares of our common stock, par value $0.0001 per share (“Common Stock”), directly to certain institutional investors pursuant to this prospectus supplement and the accomp |
|
| November 17, 2023 |
EX-99.1 Exhibit 99.1 November 15, 2023 MAIA Biotechnology Announces $4 Million Registered Direct Offering CHICAGO—(BUSINESS WIRE)— MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere- targeting immunotherapies for cancer, today announced that it has entered into a definitive agreement for the issuance and sale of |
|
| November 17, 2023 |
Form of Securities Purchase Agreement EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 15, 2023, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| November 16, 2023 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| November 15, 2023 |
Employment Agreement between Jeffrey Himmelreich and the Company, dated as of August 30, 2023. Exhibit 10.1 Date: 30 August 2023 Jeffrey C. Himmelreich Via email: [***] Re: EMPLOYMENT OFFER LETTER Dear Jeffrey: MAIA Biotechnology, Inc., a Delaware corporation (the “Company”) is pleased to offer you the Full-Time, Exempt position of Director of Accounting and Financial Reporting with terms as noted below. Please confirm your acceptance of this offer by signing and returning a copy of this le |
|
| November 15, 2023 |
Up to $7,000,000 Common Stock MAIA Biotechnology, Inc. 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-273984 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated August 23, 2023 and the Prospectus Supplement, dated September 1, 2023) Up to $7,000,000 Common Stock MAIA Biotechnology, Inc. This prospectus supplement (this “Supplement”) amends and supplements the prospectus supplement dated September 1, 2023 (the “Original Prospectus Supplem |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| November 13, 2023 |
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma EX-99.1 Exhibit 99.1 FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma • Third orphan drug designation (ODD) granted to THIO by the FDA; drug also holds ODDs for hepatocellular carcinoma and small cell lung cancer • Benefits include 7 years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing • Expected gliobl |
|
| November 7, 2023 |
Exhibit 99.1 MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO • Substantial THIO program progress including unprecedented disease control rate (DCR) of 100% in second-line non-small cell lung cancer (NSCLC) • Key THIO findings in gliomas, pediatric brain cancer, and second generation THIO-derived cancer therapies • |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q b UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41455 MAIA BIOTECHNOLOGY, INC. |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commissi |
|
| October 30, 2023 |
Exhibit 99.2 MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO Study results warrant further in vivo in-depth investigation of THIO conjugates as second generation cancer therapies. CHICAGO, IL – October 30, 2023 – MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, t |
|
| October 30, 2023 |
Exhibit 99.1 MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial • Unprecedented disease control rate (DCR) of 100% in second-line of treatment far surpasses standard of care (SoC) DCR of 53-64% • DCR is far stronger than overall response rate (ORR) in predicting o |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commis |
|
| September 28, 2023 |
MAIA Biotechnology Announces Share Repurchase Program Exhibit 99.1 MAIA Biotechnology Announces Share Repurchase Program CHICAGO, IL – September 28, 2023 – MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $800,000 of its Class A common stock through S |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commiss |
|
| September 1, 2023 |
ThinkEquity The date of this prospectus supplement is September 1, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-273984 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 23, 2023) Up to $7,000,000 Common Stock MAIA Biotechnology, Inc. We have entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (“ThinkEquity” or “Sales Agent”), relating to the sale of our common stock, par value $0.0001 per share, offere |
|
| September 1, 2023 |
Exhibit 10.1 MAIA BIOTECHNOLOGY, INC. Shares of Common Stock ATM Sales Agreement September 1, 2023 ThinkEquity LLC 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with ThinkEquity LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees tha |
|
| August 21, 2023 |
August 21, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: MAIA Biotechnology, Inc. Registration Statement on Form S-3 Filed August 14, 2023 File No. 333-273984 Acceleration Request Requested Date: Wednesday, August 23, 2023 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 u |
|
| August 15, 2023 |
Form of Subordinated Note (included in Exhibit 4.6).* Exhibit 4.6 MAIA BIOTECHNOLOGY, INC., as Issuer and •, as Trustee INDENTURE Dated as of • Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between MAIA BIOTECHNOLOGY, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b |
|
| August 15, 2023 |
Form of Senior Note (included in Exhibit 4.5).* Exhibit 4.5 MAIA BIOTECHNOLOGY, INC., as Issuer and •, as Trustee INDENTURE Dated as of • Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between MAIA BIOTECHNOLOGY, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b) and |
|
| August 15, 2023 |
As filed with the Securities and Exchange Commission on August 14, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 14, 2023 Registration No. |
|
| August 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MAIA Biotechnology, Inc. |
|
| August 8, 2023 |
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for EX-99.1 Exhibit 99.1 MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer • Filed second provisional new composition of matter patent application for MAIA’s third entirely home-grown telomere-targeting molecule • Reported 35 patients enrolled as of July 2023 in THIO-101 Phase 2 Trial • First 2 patients dosed |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 8, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q b UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41455 MAIA BIOTECHNOLOGY, INC. |
|
| July 18, 2023 |
MAIA BIOTECHNOLOGY, INC. 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 RW MAIA BIOTECHNOLOGY, INC. 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 July 18, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Mr. Joshua Gorsky Re: MAIA Biotechnology, Inc. Request to Withdraw Registration Statement on Form S-1 (File No. 333-272524) Ladies and Gent |
|
| July 11, 2023 |
EX-99.1 Exhibit 99.1 MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer • Of the first 11 patients with post-baseline scans, 9 met the disease control primary endpoint at first response assessment. CHICAGO, IL – July 11, 2023 – MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced updates on disease control data i |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 11, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| July 11, 2023 |
Issuer Free Writing Prospectus FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
|
| July 10, 2023 |
MAIA Biotechnology Reports Updates on Preliminary Survival Data for EX-99.1 Exhibit 99.1 MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer • First 2 patients dosed with THIO continue to be without documented progression for 12.2 and 11.5 months and remarkably without any new anti-cancer treatment 10.2 and 8.5 months after concluding treatment with THIO. CHICAGO, IL – July 10, 2023 – M |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 10, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| June 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MAIA Biotechnology, Inc. |
|
| June 30, 2023 |
As filed with the Securities and Exchange Commission on June 30, 2023 S-8 As filed with the Securities and Exchange Commission on June 30, 2023 Registration No. |
|
| June 30, 2023 |
Amendment No. 1 to MAIA Biotechnology, Inc. 2021 Equity Incentive Plan. Exhibit 99.2 MAIA BIOTECHNOLOGY, INC. AMENDMENT TO THE 2021 EQUITY INCENTIVE PLAN WHEREAS, MAIA Biotechnology, Inc. (the “Company”) maintains the 2021 Equity Incentive Plan (the “Plan”; capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the Plan); and WHEREAS, Article XVI of the Plan provides that the Board may amend, alter or discontinue |
|
| June 20, 2023 |
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: EX-99.1 Exhibit 99.1 MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 has enrolled 29 patients CHICAGO, IL – June 20, 2023 – MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today that 29 patients have been dosed in MAIA’s Phase 2 clinical trial, THIO-101, evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). With the addition |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 20, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission F |
|
| June 9, 2023 |
Issuer Free Writing Prospectus FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
|
| June 8, 2023 |
Amendment No. 1 to MAIA Biotechnology, Inc. 2021 Equity Incentive Plan. EX-10.19 Exhibit 10.19 MAIA BIOTECHNOLOGY, INC. AMENDMENT TO THE 2021 EQUITY INCENTIVE PLAN WHEREAS, MAIA Biotechnology, Inc. (the “Company”) maintains the 2021 Equity Incentive Plan (the “Plan”; capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the Plan); and WHEREAS, Article XVI of the Plan provides that the Board may amend, alter or d |
|
| June 8, 2023 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on June 8, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (State or other jurisdiction of incorporati |
|
| June 8, 2023 |
Calculation of Filing Fee Tables. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) MAIA BIOTECHNOLOGY, INC. |
|
| June 8, 2023 |
Form of Underwriting Agreement (including the form of Lock-Up Agreement). EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT between MAIA BIOTECHNOLOGY, INC. and THINKEQUITY LLC as Representative of the Several Underwriters MAIA BIOTECHNOLOGY, INC. UNDERWRITING AGREEMENT New York, New York June [ ], 2023 Think Equity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: The undersig |
|
| June 1, 2023 |
DRS 1 filename1.htm As submitted confidentially to the U.S. Securities and Exchange Commission on May 31, 2023. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STA |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 25, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q b UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41455 MAIA BIOTECHNOLOGY, INC. |
|
| May 8, 2023 |
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update • Reported positive topline data from the completed Part A safety lead-in of the THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and commenced recruitment in Part B randomized efficacy/dose selection • Outlined preliminary safety data from Part A survival sa |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 8, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 27, 2023 |
Underwriting Agreement by and between the Company and the Representative dated April 24, 2023. EXHIBIT 1.1 UNDERWRITING AGREEMENT between MAIA BIOTECHNOLOGY, INC. and THINKEQUITY LLC as Representative of the Several Underwriters MAIA BIOTECHNOLOGY, INC. UNDERWRITING AGREEMENT New York, New York April 24, 2023 Think Equity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: The undersigned, MA |
|
| April 27, 2023 |
The date of this prospectus supplement is April 26, 2023 Filed Pursuant to Rule 424(b)(3) Registration No. 333-269606 Prospectus Supplement No. 1 (To prospectus dated April 24, 2023) 2,222,200 Shares of Common Stock MAIA Biotechnology, Inc. This prospectus supplement supplements the prospectus dated April 24, 2023 relating to the offering of 2,222,200 shares of common stock, $0.0001 par value per share of MAIA Biotechnology, Inc. (“MAIA,” “we,” “our,” “ |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 24, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| April 27, 2023 |
MAIA Biotechnology, Inc. Announces Closing of Public Offering EXHIBIT 99.2 MAIA Biotechnology, Inc. Announces Closing of Public Offering New York, April 27, 2023 – MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its previously announced public offering of 2,555,500 shares of its common stock at a public offering price of $2.25 per share, |
|
| April 27, 2023 |
MAIA Biotechnology, Inc. Announces Pricing of Public Offering EXHIBIT 99.1 MAIA Biotechnology, Inc. Announces Pricing of Public Offering New York, April 24, 2023 — MAIA Biotechnology, Inc. (NYSE: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of an underwritten public offering of 2,222,200 shares of its common stock at a public offering price of $2.25 per |
|
| April 26, 2023 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-269606 2,222,200 Shares of Common Stock MAIA Biotechnology, Inc. We are offering 2,222,200 shares of our common stock at a public offering price of $2.25 per share. The public offering price per share of common stock was determined between us and the representative based on, among other things, the trading price of our common stock prior to the |
|
| April 21, 2023 |
ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 April 21, 2023 VIA EDGAR U. |
|
| April 21, 2023 |
ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 April 21, 2023 VIA EDGAR U. |
|
| April 21, 2023 |
As filed with the U.S. Securities and Exchange Commission on April 21, 2023. S-1/A 1 maia-s1a.htm S-1/A As filed with the U.S. Securities and Exchange Commission on April 21, 2023. Registration No. 333-269606 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 3) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (State o |
|
| April 21, 2023 |
MAIA Biotechnology, Inc. 4444 West Lake Street, Suite 1700 Chicago, IL 60606 MAIA Biotechnology, Inc. 4444 West Lake Street, Suite 1700 Chicago, IL 60606 April 21, 2023 VIA EDGAR & TELECOPY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Jimmy McNamara RE: MAIA Biotechnology, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-269606) (the “Registration Statement”) Withdrawa |
|
| April 21, 2023 |
MAIA Biotechnology, Inc. 4444 West Lake Street, Suite 1700 Chicago, IL 60606 MAIA Biotechnology, Inc. 4444 West Lake Street, Suite 1700 Chicago, IL 60606 April 21, 2023 VIA EDGAR & TELECOPY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Jimmy McNamara RE: MAIA Biotechnology, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-269606) (the “Registration Statement”) Request f |
|
| April 21, 2023 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) MAIA BIOTECHNOLOGY, INC. |
|
| April 20, 2023 |
Form of Underwriting Agreement (including the form of Lock-Up Agreement). Exhibit 1.1 UNDERWRITING AGREEMENT between MAIA BIOTECHNOLOGY, INC. and THINKEQUITY LLC as Representative of the Several Underwriters MAIA BIOTECHNOLOGY, INC. UNDERWRITING AGREEMENT New York, New York [•], 2023 Think Equity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: The undersigned, MAIA Bi |
|
| April 20, 2023 |
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
|
| April 20, 2023 |
As filed with the U.S. Securities and Exchange Commission on April 20, 2023. As filed with the U.S. Securities and Exchange Commission on April 20, 2023. Registration No. 333-269606 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 2) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (State or other jurisdiction of inc |
|
| April 20, 2023 |
Form of Pre-Funded Common Stock Purchase Warrant. Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT MAIA Biotechnology, Inc. Warrant Shares: Issue Date: April , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date a |
|
| April 20, 2023 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) MAIA BIOTECHNOLOGY, INC. |
|
| April 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 20, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| April 20, 2023 |
Exhibit 99.1 MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer CHICAGO – April 20, 2023 – MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced preliminary survival data in the Part A safety lead-in of its ongoing phase 2 trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The f |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, f |
|
| April 18, 2023 |
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models Exhibit 99.1 MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models • Study showed THIO with complete and durable responses in Hepatocellular Carcinoma (HCC), the dominant histology in primary liver cancer (90%), in in vivo models • When combined with immunotherapy checkpoint inhibitor (CPI), duration of response was further potentiated • Administration of THIO alone and in |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 18, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| April 18, 2023 |
MAIA Biotechnology, Inc. 4444 West Lake Street, Suite 1700 Chicago, IL 60606 MAIA Biotechnology, Inc. 4444 West Lake Street, Suite 1700 Chicago, IL 60606 April 18, 2023 VIA EDGAR & TELECOPY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Jimmy McNamara RE: MAIA Biotechnology, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-269606) (the “Registration Statement”) Request f |
|
| April 18, 2023 |
ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 April 18, 2023 VIA EDGAR U. |
|
| April 18, 2023 |
Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
|
| April 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 11, 2023 Date of Report (Date of earliest event reported) MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41455 83-1495913 (State or other jurisdiction of incorporation) (Commission |
|
| April 11, 2023 |
Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
